Lyell Immunopharma, Inc.
LYEL
$0.5854
-$0.0209-3.45%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 11.00K | 34.00K | 13.00K | 3.00K | 13.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.00K | 34.00K | 13.00K | 3.00K | 13.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 11.00K | 34.00K | 13.00K | 3.00K | 13.00K |
| SG&A Expenses | 14.52M | 11.77M | 12.26M | 13.49M | 13.17M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -1.44M | -730.00K | -976.00K | -1.09M | -1.08M |
| Total Operating Expenses | 61.75M | 50.54M | 51.54M | 55.58M | 59.08M |
| Operating Income | -61.74M | -50.51M | -51.53M | -55.58M | -59.07M |
| Income Before Tax | -191.94M | -44.58M | -45.81M | -60.67M | -52.93M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -191.94M | -44.58M | -45.81M | -60.67M | -52.93M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -191.94M | -44.58M | -45.81M | -60.67M | -52.93M |
| EBIT | -61.74M | -50.51M | -51.53M | -55.58M | -59.07M |
| EBITDA | -56.72M | -45.83M | -46.63M | -50.55M | -54.01M |
| EPS Basic | -0.69 | -0.17 | -0.18 | -0.24 | -0.21 |
| Normalized Basic EPS | -0.13 | -0.11 | -0.11 | -0.12 | -0.13 |
| EPS Diluted | -0.69 | -0.17 | -0.18 | -0.24 | -0.21 |
| Normalized Diluted EPS | -0.13 | -0.11 | -0.11 | -0.12 | -0.13 |
| Average Basic Shares Outstanding | 279.95M | 256.31M | 255.40M | 254.25M | 252.80M |
| Average Diluted Shares Outstanding | 279.95M | 256.31M | 255.40M | 254.25M | 252.80M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
